Last reviewed · How we verify
QL2108 injection
QL2108 injection's mechanism is not publicly available.
At a glance
| Generic name | QL2108 injection |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on QL2108 injection's mechanism of action.
Approved indications
Common side effects
Key clinical trials
- A Phase Ⅲ Comparative Study of QL2108 to Dupixent® (PHASE3)
- A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent® (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QL2108 injection CI brief — competitive landscape report
- QL2108 injection updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI